[go: up one dir, main page]

SG11201704759QA - Piperidine derivatives as hdac1/2 inhibitors - Google Patents

Piperidine derivatives as hdac1/2 inhibitors

Info

Publication number
SG11201704759QA
SG11201704759QA SG11201704759QA SG11201704759QA SG11201704759QA SG 11201704759Q A SG11201704759Q A SG 11201704759QA SG 11201704759Q A SG11201704759Q A SG 11201704759QA SG 11201704759Q A SG11201704759Q A SG 11201704759QA SG 11201704759Q A SG11201704759Q A SG 11201704759QA
Authority
SG
Singapore
Prior art keywords
hdac1
inhibitors
piperidine derivatives
piperidine
derivatives
Prior art date
Application number
SG11201704759QA
Inventor
Duzer John H Van
Ralph Mazitschek
Original Assignee
Regenacy Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenacy Pharmaceuticals Llc filed Critical Regenacy Pharmaceuticals Llc
Publication of SG11201704759QA publication Critical patent/SG11201704759QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201704759QA 2014-12-12 2015-12-11 Piperidine derivatives as hdac1/2 inhibitors SG11201704759QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462091221P 2014-12-12 2014-12-12
US201562238931P 2015-10-08 2015-10-08
PCT/US2015/065289 WO2016094824A1 (en) 2014-12-12 2015-12-11 Piperidine derivatives as hdac1/2 inhibitors

Publications (1)

Publication Number Publication Date
SG11201704759QA true SG11201704759QA (en) 2017-07-28

Family

ID=56108272

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201704759QA SG11201704759QA (en) 2014-12-12 2015-12-11 Piperidine derivatives as hdac1/2 inhibitors

Country Status (17)

Country Link
US (6) US9790180B2 (en)
EP (2) EP3725787B1 (en)
JP (1) JP6693957B2 (en)
KR (1) KR20170095964A (en)
CN (1) CN107835810A (en)
AU (2) AU2015360270B9 (en)
BR (1) BR112017012504A2 (en)
CA (1) CA2970500C (en)
CL (1) CL2017001511A1 (en)
EA (1) EA035120B1 (en)
ES (1) ES2816641T3 (en)
HK (1) HK1251566A1 (en)
IL (1) IL252828A0 (en)
MX (2) MX2017007623A (en)
PH (1) PH12017501095A1 (en)
SG (1) SG11201704759QA (en)
WO (1) WO2016094824A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2839037B1 (en) 2012-04-19 2018-12-26 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
US9403779B2 (en) 2013-10-08 2016-08-02 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors
US9949972B2 (en) 2013-12-03 2018-04-24 Acetylon Pharmaceuticals, Inc Combinations of histone deacetylase inhibitors and immunomodulatory drugs
LT3231793T (en) 2014-12-12 2020-04-27 Japan Tobacco Inc. DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND THEIR MEDICAL USE
CA2970500C (en) 2014-12-12 2023-08-29 Acetylon Pharmaceuticals, Inc. Piperidine derivatives as hdac1/2 inhibitors
TW201718516A (en) 2015-06-08 2017-06-01 艾斯特隆製藥公司 Crystalline forms of a histone deacetylase inhibitor
CN107922352B (en) 2015-06-08 2021-08-06 埃斯泰隆制药公司 Process for preparing protein deacetylase inhibitors
ES2929032T3 (en) 2016-08-08 2022-11-24 Acetylon Pharmaceuticals Inc Pharmaceutical combinations of histone deacetylase 6 inhibitors and CD20 inhibitory antibodies and uses thereof
PE20210550A1 (en) 2018-02-28 2021-03-17 Japan Tobacco Inc 4-METHYLDIHYDROPYRIMIDINONE COMPOUNDS AND THEIR PHARMACEUTICAL USE
CN110372572A (en) * 2019-08-23 2019-10-25 苏州汉德创宏生化科技有限公司 A kind of synthetic method of 4,4- difluoropiperdin -1- formyl chloride
WO2024030659A1 (en) 2022-08-05 2024-02-08 Tango Therapeutics, Inc. An hdac inhibitor for treating cancer with a modified stk11 activity or expression
WO2024167423A1 (en) 2023-02-07 2024-08-15 Captor Therapeutics S.A. Gspt1 degrader compounds

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60320957D1 (en) * 2002-03-13 2008-06-26 Janssen Pharmaceutica Nv Sulfonylderivate als histone-deacetylase-inhibitoren
CA2476296C (en) * 2002-03-13 2011-02-22 Janssen Pharmaceutica N.V. Amino-derivatives as inhibitors of histone deacetylase
EP1663953A1 (en) 2003-09-24 2006-06-07 Methylgene, Inc. Inhibitors of histone deacetylase
AR057579A1 (en) * 2005-11-23 2007-12-05 Merck & Co Inc SPIROCICLICAL COMPOUNDS AS INHIBITORS OF ACETYLASE HISTONE (HDAC)
CA2648804C (en) 2006-04-07 2014-05-27 Methylgene Inc. Benzamide derivatives as inhibitors of histone deacetylase
EP2013196B1 (en) 2006-04-26 2015-09-16 Merck Sharp & Dohme Corp. Disubstituted aniline compounds
EP2023924B1 (en) * 2006-05-18 2016-08-03 Merck Sharp & Dohme Corp. Aryl-fused spirocyclic compounds
JP2010506856A (en) * 2006-10-12 2010-03-04 スーパージェン, インコーポレイテッド Quinoline derivatives for regulating DNA methylation
JP2010120852A (en) 2007-03-09 2010-06-03 Daiichi Sankyo Co Ltd New diamide derivative
WO2009033281A1 (en) 2007-09-14 2009-03-19 Methylgene Inc. Cancer combination therapy with a selective inhibitor of histone deacetylase hdac1, hdac2 and/or hdac3 and a microtubule stabilizer
US7939546B2 (en) * 2007-10-12 2011-05-10 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
US7790746B2 (en) 2007-10-12 2010-09-07 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
EA026514B1 (en) 2010-01-22 2017-04-28 Эситайлон Фармасьютикалз Инк. Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
WO2012018499A2 (en) 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
JP6041808B2 (en) 2010-11-16 2016-12-14 アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. Pyrimidine hydroxyl amide compounds as protein deacetylase inhibitors and methods of use thereof
WO2012106343A2 (en) 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
CN102775356B (en) * 2011-05-13 2015-07-22 江苏恒谊药业有限公司 4-aminoquinazoline derivative and application thereof
KR20130077390A (en) * 2011-12-29 2013-07-09 제이더블유중외제약 주식회사 6-amino-3-carboxamidoindazole derivatives as protein kinase inhibitors
EP2839037B1 (en) 2012-04-19 2018-12-26 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
US9139583B2 (en) 2013-02-01 2015-09-22 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
EP2951153B1 (en) 2013-02-01 2019-04-03 Regenacy Pharmaceuticals, LLC Selective hdac3 inhibitors
EP3004141A4 (en) 2013-06-03 2017-05-31 Acetylon Pharmaceuticals, Inc. Histone deacetylase ( hdac) biomarkers in multiple myeloma
US9403779B2 (en) 2013-10-08 2016-08-02 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors
US9278963B2 (en) * 2013-10-10 2016-03-08 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
WO2015054355A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Hdac inhibitors, alone or in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma
US20150105409A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating nonhodgkin's lymphoma
CR20160200A (en) 2013-10-11 2016-08-29 Acetylon Pharmaceuticals Inc COMBINATIONS OF HISTONE DEACETILASE INHIBITORS AND IMMUNOMODULATING DRUGS
US9949972B2 (en) 2013-12-03 2018-04-24 Acetylon Pharmaceuticals, Inc Combinations of histone deacetylase inhibitors and immunomodulatory drugs
JP7017309B2 (en) 2013-12-20 2022-02-08 アセチロン ファーマシューティカルズ インコーポレイテッド Histone deacetylase 6 (HDAC6) biomarker in multiple myeloma
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
SG11201700094TA (en) 2014-07-07 2017-02-27 Acetylon Pharmaceuticals Inc Treatment of leukemia with histone deacetylase inhibitors
CA2963681A1 (en) 2014-10-08 2016-04-14 Acetylon Pharmaceuticals, Inc. Induction of gata2 by hdac1 and hdac2 inhibitors
CA2970500C (en) 2014-12-12 2023-08-29 Acetylon Pharmaceuticals, Inc. Piperidine derivatives as hdac1/2 inhibitors

Also Published As

Publication number Publication date
CN107835810A (en) 2018-03-23
KR20170095964A (en) 2017-08-23
EP3725787A1 (en) 2020-10-21
AU2020200846A1 (en) 2020-02-27
ES2816641T3 (en) 2021-04-05
US10968180B2 (en) 2021-04-06
CA2970500C (en) 2023-08-29
EP3292113A4 (en) 2018-07-04
US20170369441A1 (en) 2017-12-28
IL252828A0 (en) 2017-08-31
CL2017001511A1 (en) 2018-02-16
US11702389B2 (en) 2023-07-18
MX2017007623A (en) 2018-09-26
AU2015360270B9 (en) 2019-12-05
US10358421B2 (en) 2019-07-23
HK1251566A1 (en) 2019-02-01
EP3725787B1 (en) 2023-11-29
US20230348389A1 (en) 2023-11-02
WO2016094824A1 (en) 2016-06-16
AU2015360270A1 (en) 2017-07-13
US9790180B2 (en) 2017-10-17
US20160168093A1 (en) 2016-06-16
US10239837B2 (en) 2019-03-26
US20210179559A1 (en) 2021-06-17
JP2018502841A (en) 2018-02-01
US20190359569A1 (en) 2019-11-28
JP6693957B2 (en) 2020-05-13
AU2015360270B2 (en) 2019-11-28
EA201791259A1 (en) 2017-11-30
EP3292113A1 (en) 2018-03-14
PH12017501095A1 (en) 2017-10-18
MX2020002487A (en) 2020-07-13
EA035120B1 (en) 2020-04-29
BR112017012504A2 (en) 2018-01-09
EP3292113B1 (en) 2020-07-08
CA2970500A1 (en) 2016-06-16
US20180022702A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
ME03740B (en) Indole carboxamide compounds useful as kinase inhibitors
IL277167B (en) Cyclopropylamines as lsd1 inhibitors
IL277299B (en) Cyclopropylamines as lsd1 inhibitors
HK1251566A1 (en) Piperidine derivatives as hdac1/2 inhibitors
ZA201704382B (en) 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of parg
IL246785A0 (en) Benzimidazol-2-amines as midh1 inhibitors
HK1226398A1 (en) Benzimidazol-2-amines as midh1 inhibitors
HK1253572A1 (en) Pyrido-oxazinone derivatives as tnap inhibitors
PT3097084T (en) New kallikrein 7 inhibitors
HK1252767A1 (en) Pyrazol-pyridine derivatives as eaat3 inhibitors